Top 10 Lemborexant (Dayvigo) Generic Manufacturers in United Kingdom
The pharmaceutical market in the United Kingdom has seen significant growth, particularly in the generic drug sector, which accounted for approximately 80% of all prescriptions dispensed in 2020. The global market for insomnia treatments, including lemborexant (Dayvigo), is anticipated to reach USD 4.8 billion by 2026, growing at a CAGR of 7.5%. This growth is driven by increasing awareness of sleep disorders and the need for effective treatment options. In the UK, the market for generic lemborexant is poised for expansion as manufacturers seek to offer cost-effective alternatives to branded medications.
1. Teva Pharmaceutical Industries Ltd.
Teva is one of the largest generic pharmaceutical manufacturers in the UK, holding a market share of about 15%. With a production capacity that exceeds 50 billion doses annually across various categories, Teva is well-positioned to supply lemborexant generics as demand grows.
2. Mylan N.V.
Mylan, now part of Viatris, is a global leader in generic drugs with a significant presence in the UK market. The company has a production capacity of over 100 million units annually, and their generic lemborexant is expected to capture a notable share of the insomnia treatment market.
3. Sandoz (Novartis AG)
Sandoz, the generic division of Novartis, holds approximately 8% of the UK generics market. Their extensive R&D capabilities allow for the innovative formulation of lemborexant, catering to the growing demand for effective sleep aids.
4. Hikma Pharmaceuticals PLC
Hikma is a leading generic pharmaceutical company in the UK, with a market share of around 5%. The company manufactures various medications, and its entry into the lemborexant market could enhance their portfolio, addressing the increasing prevalence of insomnia.
5. Accord Healthcare Ltd.
Accord is a prominent player in the UK generic market, with a focus on high-quality medicines. The company has an extensive production capacity, facilitating the potential supply of lemborexant generics in response to rising market needs.
6. Amgen Inc.
Amgen has expanded its operations into the generic space, capturing a growing share of the UK market. Their strategic partnerships with local manufacturers position them to produce lemborexant at scale, meeting consumer demand effectively.
7. Sun Pharmaceutical Industries Ltd.
Sun Pharma is one of the largest specialty generic manufacturers globally. With a robust production capacity and a focus on research-driven generics, they are likely to enter the lemborexant market to cater to the increasing demands of insomnia treatments.
8. Aurobindo Pharma Ltd.
Aurobindo Pharma has established a strong footprint in the UK generics market. Their commitment to high-quality production and competitive pricing makes them a key player in the lemborexant segment, potentially increasing market access for patients.
9. Lupin Pharmaceuticals Inc.
Lupin has a well-diversified portfolio in the UK, with a focus on generics. Their plans to expand into the lemborexant market align with the growing trend of addressing sleep disorders, which affects a significant portion of the population.
10. Fresenius Kabi AG
Fresenius Kabi is known for its high-quality generics and biosimilars. With a strong presence in the UK market, they are well-equipped to manufacture lemborexant, which could significantly contribute to their revenue in the coming years.
Insights and Trends
The generic lemborexant market in the UK is on a trajectory of growth, driven by the increasing prevalence of sleep disorders and the demand for affordable treatment options. The generic drug market is expected to reach USD 38 billion by 2024 in the UK, emphasizing the potential for growth in this sector. Additionally, as more players enter the market, competition will foster innovation, leading to better formulations and patient accessibility. With the projected increase in the prevalence of insomnia, the market for lemborexant generics is likely to expand significantly, creating opportunities for both established and emerging manufacturers.
Related Analysis: View Previous Industry Report
